ArticleIranian journal of biotechnology2026
Assessment of Diagnostic Efficacy of Engineered ESAT-6 Linear Epitopes Based on IFN-γ Secretion in Tuberculosis.
Article in Iranian journal of biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) remains a major global health burden, with latent and active infections contributing significantly to morbidity and mortality. Effective diagnostic methods, particularly for latent tuberculosis, are essential for improving disease control and prevention. Objectives: This study focused on engineering a recombinant ESAT-6 protein to evaluate its impact on IFN-γ secretion in Peripheral blood mononuclear cells (PBMCs), a key indicator of immune response from TB patients. Materials and Methods: Following extraction of the ESAT-6 amino acid sequence from gene bank, linear epitopes were predicted and ranked based on immunogenic potential. The engineered cDNA was constructed, cloned, expressed in E. coli, and purified. Protein expression was confirmed via SDS-PAGE and Western blot analysis. PBMCs from tuberculosis patients were then exposed to varying concentrations (5, 10, and 15 μg) of the engineered ESAT-6 protein, with hemagglutinin serving as a control. Results: The engineered ESAT-6 protein, comprising 135 amino acids with an approximate molecular weight of 14 kDa, was successfully produced. The gene fragment encoding this protein was 405 bp in length. Exposure to the recombinant protein induced a dose-dependent increase in IFN-γ secretion from PBMCs compared to the control. Recognition of the linear epitopes by immune cells effectively stimulated the production of IFN-γ, highlighting the immunogenic potential of the engineered ESAT-6 protein. Conclusions: These findings demonstrate the utility of the engineered ESAT-6 protein in stimulating robust immune responses, suggesting its potential application in diagnostic assays and as a component of next-generation tuberculosis vaccines. Further research optimizing the structure of ESAT-6 could pave the way for improved tools in the fight against tuberculosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.